Company Overview and News

to your dashboard

Headline News

Broadfin Capital, LLC - All Holdings - 13F 13D 13G Filings -

Broadfin Capital, LLC has disclosed 45 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 676,005,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Broadfin Capital, LLC's top holdings are Heron Therapeutics, Inc. (NASDAQ:HRTX) , Corium International, Inc. (NASDAQ:CORI) , Retrophin, Inc. (NASDAQ:RTRX) , Horizon Pharma plc (NASDAQ:HZNP) , and Flamel Technologies S. (149-0)

Free Research Report as Corium's Revenue Grew 19.2%

2017-12-29 accesswire
LONDON, UK / ACCESSWIRE / December 29, 2017 / has just released a free earnings report on Corium International, Inc. (NASDAQ: CORI) (''Corium''). If you want access to this report all you need to do is sign up now by clicking the following link The Company posted its financial results on November 16, 2017, for the fourth quarter of the fiscal year 2017. (8-0)

Biotech Analysis Central Pharma News: Agile CRL, Roche's Purchase, Mallinckrodt's Major Buy

2017-12-28 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (103-0)

Agile Therapeutics: Sell-Off Post CRL Makes It Worth A Look

2017-12-27 seekingalpha
For Agile Therapeutics (AGRX) shareholders, 2017 is ending pretty much the way it began. At the start of the year, AGRX saw a huge drop after the company announced results from its Phase 3 SECURE study. While the company noted in its press release that the top-line results were “positive,” the market was not convinced and the disappointment led to more than 80% drop in AGRX. Last week, AGRX suffered another setback as the FDA issued a CRL for AGRX’s Twirla. (24-0)

Biotech Forum Daily Digest: Behind Fate's Rally

2017-12-26 seekingalpha
Biotech ended the previous weak, a bit better than flat thanks to big upsurge in the small cap part of the sector on Friday. (317-2)

Your Daily Pharma Scoop: Amgen Plans To Bring Back Cash, Roche Acquires Ignyta, Agile Tumbles On CRL

2017-12-26 seekingalpha
Today we will discuss Amgen’s (AMGN) plans to repatriate some of its cash holdings outside the U.S. In a SEC filing, Amgen noted that it expects to incur $6-$6.5 billion in tax expenses over time as it brings the cash back into the U.S. (651-2)

Biotech Forum Daily Digest: Synergy's CEO Leaves, Shareholders Cheer!

2017-12-22 seekingalpha
The biotech sector has a decent sized acquisition as 2017 comes to a close.  Roche is buying oncology concern Ignyta for a 75% premium.  M&A should see uptick in 2018. (408-1)

FDA declines to approve Agile's contraceptive patch - Channel NewsAsia

2017-12-22 channelnewsasia
REUTERS: Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods. (24-0)

FDA declines to approve Agile's contraceptive patch

2017-12-22 reuters
(Reuters) - Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company’s contraceptive patch, citing deficiencies related to its adhesion test methods. (24-0)

Integrated BioSci Research On Corium: A Stellar Investing Opportunity

2017-11-24 seekingalpha
The multi-billion dollars market for Alzheimer’s disease is lucrative. And, the company has a small market cap to warrant much further upsides. (90-0)

Corium International's (CORI) CEO Peter Staple on Q4 2017 Results - Earnings Call Transcript

2017-11-17 seekingalpha
Good day, ladies and gentlemen and welcome to Corium International's Conference Call for its Fourth Fiscal Quarter and Year-End 2017. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] And as a reminder, this conference call maybe recorded. (24-1)

BRIEF-Corium reports Q4 loss per share $0.36

2017-11-16 reuters
* Corium International Inc - ‍Cash and cash equivalents as of September 30, 2017 were $57.5 million​ Source text for Eikon: Further company coverage: (8-0)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Bioscience Catalysts: Global Blood Therapeutics And Vanda Pharmaceuticals

2017-10-31 seekingalpha
The bioscience catalyst series seeks to help readers making sense of the notable life science runners. (61-1)

CUSIP: 21887L107